Diabetes is a common complication of cystic fibrosis (CF) that affects approximately 20% of adolescents and 40%–50% of adults with CF. The age at onset of CF-related diabetes (CFRD) (marked by clinical diagnosis and treatment initiation) is an important measure of the disease process. DNA variants associated with age at onset of CFRD reside in and near SLC26A9. Deep sequencing of the SLC26A9 gene in 762 individuals with CF revealed that 2 common DNA haplotypes formed by the risk variants account for the association with diabetes. Single-cell RNA sequencing (scRNA-Seq) indicated that SLC26A9 is predominantly expressed in pancreatic ductal cells and frequently coexpressed with CF transmembrane conductance regulator (CFTR) along with transcription factors that have binding sites 5′ of SLC26A9. These findings were replicated upon reanalysis of scRNA-Seq data from 4 independent studies. DNA fragments derived from the 5′ region of SLC26A9-bearing variants from the low-risk haplotype generated 12%–20% higher levels of expression in PANC-1 and CFPAC-1 cells compared with the high- risk haplotype. Taken together, our findings indicate that an increase in SLC26A9 expression in ductal cells of the pancreas delays the age at onset of diabetes, suggesting a CFTR-agnostic treatment for a major complication of CF.
Anh-Thu N. Lam, Melis A. Aksit, Briana Vecchio-Pagan, Celeste A. Shelton, Derek L. Osorio, Arianna F. Anzmann, Loyal A. Goff, David C. Whitcomb, Scott M. Blackman, Garry R. Cutting
Title and authors | Publication | Year |
---|---|---|
Impact of Gene Modifiers on Cystic Fibrosis Phenotypic Profiles: A Systematic Review
Ward A, Mauleon R, Ooi CY, Rosic N |
Human Mutation | 2024 |
SLC26A9 in airways and intestine: secretion or absorption?
Kunzelmann K, Centeio R, Ousingsawat J, Talbi K, Seidler U, Schreiber R |
Channels (Austin, Tex.) | 2023 |
Single-Cell RNA Sequencing Reveals New Basic and Translational Insights in the Cystic Fibrosis Lung.
Januska MN, Walsh MJ |
American journal of respiratory cell and molecular biology | 2023 |
Cystic Fibrosis–Related Diabetes Workshop: Research Priorities Spanning Disease Pathophysiology, Diagnosis, and Outcomes
Putman MS, Norris AW, Hull RL, Rickels MR, Sussel L, Blackman SM, Chan CL, Ode KL, Daley T, Stecenko AA, Moran A, Helmick MJ, Cray S, Alvarez JA, Stallings VA, Tuggle KL, Clancy JP, Eggerman TL, Engelhardt JF, Kelly A |
Diabetes | 2023 |
Cystic Fibrosis-Related Diabetes Workshop: Research Priorities Spanning Disease Pathophysiology, Diagnosis, and Outcomes.
Putman MS, Norris AW, Hull RL, Rickels MR, Sussel L, Blackman SM, Chan CL, Ode KL, Daley T, Stecenko AA, Moran A, Helmick MJ, Cray S, Alvarez JA, Stallings VA, Tuggle KL, Clancy JP, Eggerman TL, Engelhardt JF, Kelly A |
Diabetes care | 2023 |
New discoveries in the field of metabolism by applying single-cell and spatial omics
Xie B, Gao D, Zhou B, Chen S, Wang L |
Journal of Pharmaceutical Analysis | 2023 |
Pathogenic Relationships in Cystic Fibrosis and Renal Diseases: CFTR, SLC26A9 and Anoctamins
Kunzelmann K, Ousingsawat J, Kraus A, Park JH, Marquardt T, Schreiber R, Buchholz B |
International journal of molecular sciences | 2023 |
SLC26A9 as a Potential Modifier and Therapeutic Target in Cystic Fibrosis Lung Disease
G Gorrieri, F Zara, P Scudieri |
Biomolecules | 2022 |
The role of genetic modifiers, inflammation and CFTR in the pathogenesis of Cystic fibrosis related diabetes
S Hasan, S Soltman, C Wood, SM Blackman |
Journal of Clinical & Translational Endocrinology | 2022 |
Diabetes and Its Cardiovascular Complications: Comprehensive Network and Systematic Analyses
H Wu, V Norton, K Cui, B Zhu, S Bhattacharjee, Y Lu, B Wang, D Shan, S Wong, Y Dong, S Chan, D Cowan, J Xu, D Bielenberg, C Zhou, H Chen |
Frontiers in Cardiovascular Medicine | 2022 |
Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung disease
J Gong, G He, C Wang, C Bartlett, N Panjwani, S Mastromatteo, F Lin, K Keenan, J Avolio, A Halevy, M Shaw, M Esmaeili, G Côté-Maurais, D Adam, S Bégin, C Bjornson, M Chilvers, J Reisman, A Price, M Parkins, R van Wylick, Y Berthiaume, L Bilodeau, D Mateos-Corral, D Hughes, M Smith, N Morrison, J Brusky, E Tullis, A Stephenson, B Quon, P Wilcox, W Leung, M Solomon, L Sun, E Brochiero, T Moraes, T Gonska, F Ratjen, J Rommens, L Strug |
npj Genomic Medicine | 2022 |
Pleiotropic modifiers of age-related diabetes and neonatal intestinal obstruction in cystic fibrosis.
Aksit MA, Ling H, Pace RG, Raraigh KS, Onchiri F, Faino AV, Pagel K, Pugh E, Stilp AM, Sun Q, Blue EE, Wright FA, Zhou YH, Bamshad MJ, Gibson RL, Knowles MR, Cutting GR, Blackman SM |
The American Journal of Human Genetics | 2022 |
Modifier Factors of Cystic Fibrosis Phenotypes: A Focus on Modifier Genes
Mésinèle J, Ruffin M, Guillot L, Corvol H |
International journal of molecular sciences | 2022 |
Physiology and pathophysiology of human airway mucus
Hill DB, Button B, Rubinstein M, Boucher RC |
Physiological reviews | 2022 |
ISPAD Clinical Practice Consensus Guidelines 2022: Management of cystic fibrosis‐related diabetes in children and adolescents
Ode KL, Ballman M, Battezzati A, Brennan A, Chan CL, Hameed S, Ismail HM, Kelly A, Moran AM, Rabasa\u2010Lhoret R, Saxby NA, Craig ME |
Pediatric Diabetes | 2022 |
Endocrine Complications of Cystic Fibrosis
Kelly A, Marks BE, Stalvey MS |
Clinics in Chest Medicine | 2022 |
Cystic Fibrosis-Related Diabetes (CFRD): Overview of Associated Genetic Factors
F Iafusco, G Maione, FM Rosanio, E Mozzillo, A Franzese, N Tinto |
Diagnostics | 2021 |
The Potential Causes of Cystic Fibrosis-Related Diabetes
L Coderre, L Debieche, J Plourde, R Rabasa-Lhoret, S Lesage |
Frontiers in Endocrinology | 2021 |
SLC26A9 SNP rs7512462 is not associated with lung disease severity or lung function response to ivacaftor in cystic fibrosis patients with G551D-CFTR
AC Eastman, RG Pace, H Dang, MA Aksit, B Vecchio-Pagán, AT Lam, WK O'Neal, SM Blackman, MR Knowles, GR Cutting |
Journal of Cystic Fibrosis | 2021 |
Pharmacological Modulation of Ion Channels for the Treatment of Cystic Fibrosis
MC Pinto, IA Silva, MF Figueira, MD Amaral, M Lopes-Pacheco |
Journal of Experimental Pharmacology | 2021 |
Synergy in Cystic Fibrosis Therapies: Targeting SLC26A9
MC Pinto, MC Quaresma, IA Silva, V Railean, SS Ramalho, MD Amaral |
International journal of molecular sciences | 2021 |
Cystic fibrosis being a polyendocrine disease (Review)
N Chagay, G Khayt, T Vdovina, A Shaforost |
Problems of Endocrinology | 2021 |
Precision medicine for pancreatic diseases
CA Shelton, DC Whitcomb |
Current Opinion in Gastroenterology | 2020 |
Genetic Variation Near chrXq22-q23 Is Linked to Emotional Functioning in Cystic Fibrosis
E Barbato, B Daly, S Douglas, M Kerr, P Litman, R Darrah |
Biological research for nursing | 2020 |
Genetic Modifiers of Cystic Fibrosis-Related Diabetes Have Extensive Overlap With Type 2 Diabetes and Related Traits
MA Aksit, RG Pace, B Vecchio-Pagán, H Ling, JM Rommens, PY Boelle, L Guillot, KS Raraigh, E Pugh, P Zhang, LJ Strug, ML Drumm, MR Knowles, GR Cutting, H Corvol, SM Blackman |
The Journal of clinical endocrinology and metabolism | 2019 |
The genetics and genomics of cystic fibrosis
N Sharma, GR Cutting |
Journal of Cystic Fibrosis | 2019 |
Genetic variation in CFTR and modifier loci may modulate cystic fibrosis disease severity
A Paranjapye, M Ruffin, A Harris, H Corvol |
Journal of Cystic Fibrosis | 2019 |